Clinical Trials

150 enrolled

Breast Neoplasms

NCT05806671 2023-04-10

Dalpiciclib Plus Fulvestrant With Pyrotinib in Hormone Receptor-positive, HER2-low Advanced Breast Cancer That Progressed on Previous CDK4/6i Plus AI Therapy

30 enrolled

Breast Neoplasms

NCT05764941 2023-03-27

Inetetamab Combined With Pyrotinib and Vinorelbine as First-line to Third-line Treatment for HER2-positive Metastatic Breast Cancer

Breast Neoplasms

NCT03772353 2023-03-07

PLEASURABLE

59 enrolled

Breast Neoplasms

NCT04582968 2023-01-18

Pyrotinib Combined With Brain Radiotherapy in Breast Cancer Patients With Brain Metastases

39 enrolled

BreastCNS

Brain Neoplasms, Breast Neoplasms

NCT05577923 2022-10-13

Exploring Whether Disease-free Intervals Can Guide Endocrine Combined Targeted Therapy for ER+/HER2+ Advanced Breast Cancer (T-sunflower)

126 enrolled

Breast Neoplasms

NCT05561686 2022-09-30

Real-world Study of Pyrotinib in Neoadjuvant Therapy for HER2-positive Breast Cancer

HER2-positive Breast Cancer

NCT03805399 2022-08-10

FUTURE

140 enrolled

Triple Negative Breast Neoplasms

NCT04355858 2022-07-26

MULAN

319 enrolled

Breast Neoplasms, Neoplasm Metastasis

NCT05429294 2022-06-23

Novel Double Target Therapy Combined With Chemotherapy in First-line Treatment of HER2+ Breast Cancer, MA-BC-II-038

209 enrolled

HER2-positive Breast Cancer

NCT05429684 2022-06-23

Precise Therapy for Refractory HER2 Positive Advanced Breast Cancer

Phase 3 Unknown

120 enrolled

HER2+ Breast Cancer

NCT04334330 2022-05-02

Palbociclib, Trastuzumab,Pyrotinib and Fulvestrant Treatment in Patients With Brain Metastasis From ER/PR Positive, HER-2 Positive Breast Cancer: A Multi-center, Prospective Study in China

34 enrolled

BreastCNS

Brain Neoplasms, Breast Neoplasms

NCT04605575 2022-04-26

Pyrotinib Plus Vinorelbine in Participants With HER2-positive Previously Treated Locally Advanced or Metastatic Breast Cancer

208 enrolled

Breast Diseases, Breast Neoplasms

NCT05346861 2022-04-26

Pyrotinib Rechallenge in Her2-positive Metastatic Breast Cancer Pretreated With Pyrotinib and Trastuzumab

Phase 3 Unknown

240 enrolled

Breast Neoplasms

NCT05030519 2022-03-02

A Study of Diarrhea and Intestinal Flora Changes Caused by Pyrotinib in Breast Cancer

50 enrolled

Breast Neoplasms

NCT05255523 2022-02-24

Pyrotinib Plus Trastuzumab After First-line TH (P) Treatment With HER-2 Positive Breast Cancer

Advanced Breast Cancer

NCT05111444 2021-11-08

Camrelizumab Plus Pyrotinib Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

65 enrolled

Stomach Neoplasms

NCT05076695 2021-10-13

NeoTPPF

37 enrolled

Estrogen Receptor-positive Breast Cancer

NCT04380012 2021-07-15

A Clinical Study of Pyrotinib in Patients With HER2-positive Advanced Colorectal Cancer

40 enrolled

Colorectal Neoplasms

NCT04963595 2021-07-15

Pyrotinib and Vinorelbine Tartrate Capsules With or Without Inetetamab for First Line Treatment in Patients With Trastuzumab-resistant HER2-positive Advanced Breast Cancer

Breast Neoplasms

NCT04960943 2021-07-14

Efficacy and Safety of Pyrotinib in HER2 Positive Gastrointestinal Tumors

Digestive System Neoplasms

NCT04760431 2021-06-02

TKIs vs. Pertuzumab in HER2+ Breast Cancer Patients With Active Brain Metastases (HER2BRAIN)

120 enrolled

CNS

Brain Neoplasms

NCT04900311 2021-05-25

Pyramid

490 enrolled

HER2+ Early or Locally Advanced Breast Cancer

NCT04899128 2021-05-24

Treatment With Pyrotinib-Based Therapy in Lapatinib Resistant HER2-Positive Metastatic Breast Cancer

Breast Neoplasms

NCT04683445 2020-12-24

Efficacy and Safety of Eribulin in the Treatment of Advanced Breast Cancer

80 enrolled

Breast Neoplasms

NCT04681911 2020-12-23

Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer

71 enrolled

Breast Neoplasms

NCT04609540 2020-12-16

Pyrotinib Combined With Trastuzumab And Chemotherapy in HER2-positive MBC

200 enrolled

Breast Neoplasms

NCT04639271 2020-11-20

Pyrotinib, Trastuzumab And Abraxane in HER2-positive MBC With Brain Metastasis

Breast Neoplasms

NCT04255056 2020-02-07

PRETTY

27 enrolled

Breast Neoplasms

NCT04246502 2020-02-05

Capecitabine Plus Pyrotinib Versus Capecitabine Plus Trastuzumab and Pertuzumab in the First-line Treatment of HER2-positive Metastatic Breast Cancer

200 enrolled

Breast Neoplasms

NCT04227041 2020-01-14

A Study of Pyrotinib Combined With Capecitabine for Metastatic HER-2 Positive Colorectal Cancer

34 enrolled

HER-2 Positive Colorectal Cancer

NCT04179656 2019-11-27

The Basket Study of Pyrotinib Maleate for HER2-Postive Solid Tumor

Other solid neoplasm

Solid Tumor

NCT04095390 2019-09-19

INPHASE

Breast Neoplasms

NCT04063462 2019-08-21

Phase 2 Study of Pyrotinib in Previously Treated Patients With NSCLC Having EGFR or ERBB2 Exon 20 Insertion Mutation

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03756064 2019-08-13

Neoadjuvant Study of Pyrotinib in Patients With HER2 Positive Breast Cancer

Phase NA Unknown

Breast Diseases, Breast Neoplasms

NCT03997539 2019-06-25

A Study of Pyrotinib Plus Vinorelbine in Comparison With Treatment of Physician's Choice in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer

256 enrolled

Breast Neoplasms

NCT03910712 2019-04-10

Pyrotinib

250 enrolled

Breast Diseases, Breast Neoplasms

NCT03843749 2019-02-18

Pyrotinib in Combination With Trastuzumab in Treatment-refractory, HER2-positive Metastatic Colorectal Cancar.

Phase NA Unknown

30 enrolled

Colorectal Neoplasms

NCT03412383 2018-01-30

Pyrotinib in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer

14 enrolled

Breast Neoplasms

NCT02535507 2015-08-28

Efficacy and Safety of Pyrotinib in Patients With HER2 Mutation Advanced Non-Small Cell Lung Cancer